Harvard Bioscience Inc

NASDAQ:HBIOUnited States

Nov 7, 2024

Show headlines and story abstract

• -- Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q3 Loss $-0.02 Per Share, from 7:10AM ET on Thursday Nov 07, 2024 by MT Newswires

  7:10AM ET on Thursday Nov 07, 2024 by MT Newswires
  Companies Mentioned: HBIO
  07:10 AM EST, 11/07/2024 (MT Newswires) -- ...

• -- Earnings Flash (HBIO) HARVARD BIOSCIENCE Reports Q3 Revenue $22M, from 7:10AM ET on Thursday Nov 07, 2024 by MT Newswires

  7:10AM ET on Thursday Nov 07, 2024 by MT Newswires
  Companies Mentioned: HBIO
  07:10 AM EST, 11/07/2024 (MT Newswires) -- ...

• Harvard Bioscience Announces Third Quarter 2024 Financial Results, from 7:00AM ET on Thursday Nov 07, 2024 by Dow Jones

  7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: HBIO
  changes on cash and cash equivalents 370 (194) 223 (137) --- ------ --- ------ ------- --- ------ Increase in cash and cash equivalents 521 1,016 286 832 Cash and cash equivalents at the beginning of period 4,048 4,324 4,283 4,508 Cash and cash equivalents at the end of period $ 4,569 $ 5,340 $ 4,569 $ 5,340 === ====== === ====== ======= === ====== HARVARD BIOSCIENCE, INC. Reconciliation of GAAP to Non-GAAP Financial Measures (unaudited) (in thousands, except per share data and percentages) Three Months Ended Nine Months Ended ---------------------------- ---------------------------- September 30, September 30, September 30, September 30, 2024 2023 2024 2023 ------------- ------------- ------------- ------------- GAAP operating (loss) income $(1,874) $ (933) $ (6,222) $ 1,612 Stock-based compensation 1,053 1,363 3,379 3,618 Acquired asset depreciation & amortization 1,343 1,369 4,017 4,167 Other operating expenses (1) 179 - 1,394 - Other adjustments 137 42 256 450 Adjusted operating income $ 838 $ 1,841 $ 2,824 $ 9,847 ====== ==== ====== ==== ======= === ====== ==== Operating margin (8.5%) (3.7%) (8.9%) 1.9% Adjusted operating margin 3.8% 7.3% 4.1% 11.7% ----------------- ------ --- ------ --- ------- ------ --- GAAP net loss $(4,802) $(1,239) $(12,423) $(1,597) Stock-based compensation 1,053 1,363 3,379 3,618 Acquired asset depreciation & amortization 1,343 1,369 4,015 4,167 Other operating expenses (1) 179 - 1,394 - Pension settlement expense 1,243 - 1,243 - Other adjustments 137 42 256 46 (Gain) loss on equity securities - (1,208) 1,593 374 Income taxes (214) 196 377 (1,919) Adjusted net (loss) income (1,061) 523 (166) 4,689 ------ --- ------ ---- ------- ------ ---- Depreciation & amortization 475 405 1,383 1,054 Interest and other expense, net 1,374 837 3,197 3,095 Adjusted income taxes (2) 525 481 (209) 2,063 ------ ---- ------ ---- ------- ------ ---- Adjusted EBITDA $ 1,313 $ 2,246 $ 4,205 $10,901 ====== ==== ====== ==== ======= === ====== ==== Adjusted EBITDA margin 6.0% 8.9% 6.0% 13.0% ----------------- ------ --- ------ --- ------- ------ --- Diluted loss per share (GAAP) $ (0.11) $ (0.03) $ (0.29) $ (0.04) ====== === ====== === ======= ====== === Diluted adjusted earnings per share $ (0.02) $ 0.01 $ (0.00) $ 0.11 ====== === ====== ==== ======= ====== ==== Weighted-average common shares: Diluted GAAP 43,614 42,688 43,499 42,345 ====== ==== ====== ==== ======= === ====== ==== Diluted Adjusted 43,614 44,563 43,499 44,195 ====== ==== ====== ==== ======= === ====== ==== (1) Other operating expenses for the three months ended September 30, 2024 includes $0.2 million of restructuring-related charges. Other operating expenses for the nine months ended September 30, 2024 includes a $0.5 million commission fee paid in connection with the receipt of employee retention credits, a loss of $0.3 million related to an unclaimed property audit, and $0.6 million of restructuring-related charges. (2) Adjusted income taxes includes the tax effect of adjusting for the reconciling items using the tax rates in the jurisdictions in which the reconciling items arise. ----------------------------------------------------------------------------- September 30, 2024 December 31, 2023 ---------------------- --------------------- Debt, including unamortized deferred financing costs $ 37,858 $ 36,563 Unamortized deferred financing costs 492 560 Cash and cash equivalents (4,569) (4,283) Net debt $ 33,781 $ 32,840 === ============= === ============
  

• *DJ Harvard Bioscience 3Q Loss/Shr 11c >HBIO, from 7:00AM ET on Thursday Nov 07, 2024 by Dow Jones

  7:00AM ET on Thursday Nov 07, 2024 by Dow Jones
  Companies Mentioned: HBIO